Compare PGY & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | FTRE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2021 | 2023 |
| Metric | PGY | FTRE |
|---|---|---|
| Price | $18.43 | $21.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $28.91 | $20.67 |
| AVG Volume (30 Days) | ★ 2.3M | 1.3M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.43 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | $1,301,360,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $12.53 | N/A |
| Revenue Next Year | $15.85 | $3.05 |
| P/E Ratio | $23.91 | ★ N/A |
| Revenue Growth | ★ 26.07 | 1.00 |
| 52 Week Low | $10.40 | $8.55 |
| 52 Week High | $31.54 | $21.39 |
| Indicator | PGY | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 66.37 |
| Support Level | $16.34 | $15.94 |
| Resistance Level | $19.14 | N/A |
| Average True Range (ATR) | 0.99 | 1.08 |
| MACD | -0.21 | 0.15 |
| Stochastic Oscillator | 31.57 | 58.86 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.